Abstract |
Spirogermanium was given as a 90 minute infusion to 47 eligible patients with refractory Hodgkin's (9 patients) or non-Hodgkin's lymphoma (38 patients). The schedule was 80 mg/m2 three times a week for the first two weeks and 100 mg/m2, 3 times a week, for the two subsequent weeks. In case of response or stable disease, the treatment was continued with biweekly infusions of 100 mg/m2 until tumor progression. In 64% of cases, three or more combinations had been previously administered; 66% of patients presented an extra-lymphatic spread of disease. Two patients with Hodgkin's disease showed a partial response of 11 and 23 weeks and two patients with non-Hodgkin's lymphoma achieved a complete response of 12 and 24 weeks. Overall, 14 patients showed a tumor progression within the first month of treatment. The main toxicity was neurological, with dizziness and lethargy during the infusion in 50% of cases. Hematologic toxicity was almost absent. Spirogermanium is ineffective in heavily pretreated patients with non-Hodgkin's lymphoma. The confirmed lack of activity in patients with refractory malignant lymphoma and the need of repeated and prolonged infusions definitely discourage the clinical use of the drug.
|
Authors | C Sessa, W ten Bokkel Huinik, M Clavel, L M Lev, R A Joss, J Renard, F Cavalli |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 7
Issue 2-3
Pg. 219-22
(Jul 1989)
ISSN: 0167-6997 [Print] United States |
PMID | 2793376
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Organometallic Compounds
- Spiro Compounds
- spirogermanium
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Drug Evaluation
- Female
- Hodgkin Disease
(drug therapy)
- Humans
- Lymphoma
(drug therapy)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Organometallic Compounds
(adverse effects, therapeutic use)
- Spiro Compounds
(adverse effects, therapeutic use)
|